Acute on Chronic Hepatic Failure
10
3
4
2
Key Insights
Highlights
Success Rate
40% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
30.0%
3 terminated out of 10 trials
40.0%
-46.5% vs benchmark
10%
1 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (10)
The Effects of Double Plasma Molecular Adsorption System in Acute on Chronic Liver Failure Patients
Biomarkers in Liver Failure
The Safety ,Tolerability and Efficacy Study of HepaCure in Chinese Subjects with Acute-On-Chronic Liver Failure
Allogenic Bone Marrow Mesenchymal Stem Cell Therapy in Acute-on-chronic Liver Failure
Comparison of Inflammatory Profiles and Regenerative Potential in Alcoholic Liver Disease
Hepa Wash Treatment of Patients With Acute-on-Chronic Liver Failure in Intensive Care Units
Efficacy of Granulocyte Colony-stimulating Factor and Erythropoetin for Patients With Acute-on-chronic Liver Failure
A Trial of Ribavirin in Patients With ACLF Due to Hepatitis E Virus
Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF
Single Pass Albumin Dialysis in Patients With Cirrhosis